Download PDF
Semin Respir Crit Care Med 2002; 23(1): 069-082
DOI: 10.1055/s-2002-20590
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Management of Acute Ischemic Stroke

Phillip Scott
  • Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
07 March 2002 (online)

    Permissions and Reprints

ABSTRACT

Prior to 1995 no proven therapy existed for acute ischemic stroke. In 1996 the U.S. Food and Drug Administration approved the use of intravenous rt-PA in acute stroke based largely on the results of a two-part trial sponsored by the National Institutes of Health and National Institute of Neurological Disorders and Stroke (NIH/NINDS). Five years following approval, however, thrombolytic treatment remains underutilized, occurring in only 1 to 2% of all stroke patients. The medical community is now being called upon to organize systems capable of delivering acute stroke care in a time-urgent manner not previously contemplated. Critical care specialists may be called upon to treat stroke occurring in hospitalized patients or to continue care initiated in the emergency department. This article briefly reviews the pathogenesis of cellular injury in stroke and its initial evaluation and care and then focuses on the data involving thrombolytic reperfusion. Special attention is given to postthrombolytic critical care issues as these represent an important determinant in patient outcome. Secondary stroke prevention strategies and complication management are discussed along with general intensive care issues for the stroke patient.

KEYWORD

Ischemic stroke - thrombolytic therapy - anticoagulation - antiplatelet therapy - treatment

REFERENCES

  • 1 2001 Heart and Stroke Statistical Update. Dallas, Tex.: American Heart Association; 2000
  • 2 Broderick J, Brott T, Kothari R. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks.  Stroke . 1998;  29 415-421
    PubMedGoogle Scholar
  • 3 Broderick J P. Practical considerations in the early treatment of ischemic stroke.  Am Fam Phys . 1998;  57 73-80
    PubMedGoogle Scholar
  • 4 Pulsinelli W. Pathophysiology of acute ischemic stroke.  Lancet . 1992;  339(8792) 533-6
    CrossrefPubMedGoogle Scholar
  • 5 Fischer M, Garcia J. Evolving stroke and the ischemic penumbra.  Neurology . 1996;  47 884-888
    PubMedGoogle Scholar
  • 6 Hossmann K. Viability thresholds and the penumbra of focal ischemia.  Ann Neurol . 1994;  36 557-565
    CrossrefPubMedGoogle Scholar
  • 7 Astrup J, Siesjo B, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra.  Stroke . 1981;  12 723-725
    CrossrefPubMedGoogle Scholar
  • 8 Siesjo B, Agardh C, Bengtsson F. Free radicals and brain damage.  Cerebrovasc Brain Metab Rev . 1989;  1 165-211
    PubMedGoogle Scholar
  • 9 Kaplan B, Brint S, Tanabe J, Jacewicz M, Wang X, Pulsinelli W. Temporal threshold for neocortical infarction in rats subjected to reversible focal cerebral ischemia.  Stroke . 1991;  22 1032-1039
    PubMedGoogle Scholar
  • 10 Ginsberg M D, Sternau L L, Globus M Y, Dietrich W D, Busto R. Therapeutic modulation of brain temperature: relevance to ischemic brain injury.  Cerebrovasc Brain Metab Rev . 1992;  4 189-225
    PubMedGoogle Scholar
  • 11 Kothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke.  Stroke . 1995;  26 937-941
    CrossrefPubMedGoogle Scholar
  • 12 Pulsinelli W A, Waldman S, Rawlinson D, Plum F. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat.  Neurology . 1982;  32 1239-1246
    PubMedGoogle Scholar
  • 13 DeGraba T J, Hallenbeck J M, Pettigrew K D, Dutka A J, Kelly B J. Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials.  Stroke . 1999;  30 1208-1212
    PubMedGoogle Scholar
  • 14 Brott T, Adams Jr P H, Olinger C P. Measurements of acute cerebral infarction: a clinical examination scale.  Stroke . 1989;  20 864-870
    CrossrefPubMedGoogle Scholar
  • 15 Anonymous. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997 28: 2109-2118
    Google Scholar
  • 16 Albers G W, Sherman D G, Gress D R, Paulseth J E, Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials.  Ann Neurol . 1991;  30 511-518
    CrossrefPubMedGoogle Scholar
  • 17 Kannel W B, Abbott R D, Savage D D, McNamara P M. Epidemiologic features of chronic atrial fibrillation: the Framingham study.  N Engl J Med . 1982;  306 1018-1022
    CrossrefPubMedGoogle Scholar
  • 18 Kanter M C, Tegeler C H, Pearce L A. Carotid stenosis in patients with atrial fibrillation: prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study.  Arch Intern Med . 1994;  154 1372-1377
    CrossrefPubMedGoogle Scholar
  • 19 Morgenstern L B, Luna-Gonzales H, Huber Jr C J. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis.  Ann Emerg Med . 1998;  32 297-304
    PubMedGoogle Scholar
  • 20 Edlow J A, Wyer P C. Evidence-based emergency medicine/ clinical question: how good is a negative cranial computed tomographic scan result in excluding subarachnoid hemorrhage?.  Ann Emerg Med . 2000;  36 507-516
    PubMedGoogle Scholar
  • 21 vonKummer R, Bozzao L, Manelfe C. Early CT Diagnosis of Hemispheric Brain Infarction.  Berlin, Heidelberg: Springer-Verlag 1995
    Google Scholar
  • 22 Wolpert S M, Bruckmann H, Greenlee R, Wechsler L, Pessin M S, del Zoppo J G. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group.  Am J Neuroradiol . 1993;  14 3-13
    PubMedGoogle Scholar
  • 23 Mori E, Yoneda Y, Tabuchi M. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.  Neurology . 1992;  42 976-982
    CrossrefPubMedGoogle Scholar
  • 24 Anonymous. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [see comments].  N Engl J Med . 1995;  333 1581-1587
    CrossrefPubMedGoogle Scholar
  • 25 Hacke W, Kaste M, Fieschi C. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) [see comments].  JAMA . 1995;  274 1017-1025
    CrossrefPubMedGoogle Scholar
  • 26 Hacke W, Kaste M, Fieschi C. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators [see comments].  Lancet . 1998;  352 1245-1251
    CrossrefPubMedGoogle Scholar
  • 27 Clark W M, Wissman S, Albers G W, Jhamandas J H, Madden K P, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke [see comments].  JAMA . 1999;  282 2019-2026
    CrossrefPubMedGoogle Scholar
  • 28 Anonymous. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group [comment] [see comments].  Lancet . 1995;  346 1509-1514
    PubMedGoogle Scholar
  • 29 Anonymous. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group [see comments].  N Engl J Med . 1996;  335 145-150
    CrossrefPubMedGoogle Scholar
  • 30 Donnan G A, Davis S M, Chambers B R. Trials of streptokinase in severe acute ischaemic stroke.  Lancet . 1995;  345 578-579
    CrossrefPubMedGoogle Scholar
  • 31 Kwiatkowski T G, Libman R B, Frankel M. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group [see comments].  N Engl J Med . 1999;  340 1781-1787
    CrossrefPubMedGoogle Scholar
  • 32 Tanne D, Gorman M J, Bates V E. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience.  Stroke . 2000;  31 370-375
    PubMedGoogle Scholar
  • 33 Anonymous. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial.  Stroke . 1997;  28 2119-2125
    PubMedGoogle Scholar
  • 34 Clark W M, Albers G W, Madden K P, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.  Stroke . 2000;  31 811-816
    CrossrefPubMedGoogle Scholar
  • 35 Katzan I L, Sila C A, Furlan A J. Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey.  Stroke . 2001;  32 861-865
    PubMedGoogle Scholar
  • 36 Lopez-Yunez A M, Bruno A, Williams L S, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.  Stroke . 2001;  32 12-16
    PubMedGoogle Scholar
  • 37 Albers G W, Bates V E, Clark W M, Bell R, Verro P, Hamilton S A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study [see comments].  JAMA . 2000;  283 1145-1150
    CrossrefPubMedGoogle Scholar
  • 38 Tanne D, Bates V E, Verro P. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.  Neurology . 1999;  53 424-427
    PubMedGoogle Scholar
  • 39 Grond M, Stenzel C, Schmulling S. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach.  Stroke . 1998;  29 1544-1549
    PubMedGoogle Scholar
  • 40 Chiu D, Krieger D, Villar-Cordova C, Kasner S E, Morgenstern L B P B, Yatsu F M, Grotta J C. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.  Stroke . 1998;  29 18-22
    PubMedGoogle Scholar
  • 41 Chapman K M, Woolfenden A R, Graeb D. Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian hospital's experience.  Stroke . 2000;  31 2920-2924
    PubMedGoogle Scholar
  • 42 Hanson S K, Brauer D J, Anderson D C. Stroke treatment in the community (STIC): intravenous rt-PA in community practice.  Neurology . 1998;  50 A155-156
    CrossrefPubMedGoogle Scholar
  • 43 Smith R W, Scott P A, Grant R J, Chudnofsky C R, Frederiksen S M. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.  Acad Emerg Med . 1999;  6 618-625
    PubMedGoogle Scholar
  • 44 Scott P A, Smith R W, Chudnofsky C R. Emergency physician administration of rt-PA in acute stroke: analysis of treatment and outcome.  Stroke . 1999;  30 244
    PubMedGoogle Scholar
  • 45 Marler J R, Tilley B C, Lu M. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.  Neurology . 2000;  55 1649-1655
    CrossrefPubMedGoogle Scholar
  • 46 Adams H P, Brott T G, Furlan A J. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke.  Circulation . 1996;  94 1167-1174
    CrossrefPubMedGoogle Scholar
  • 47 Anonymous. Practice advisory: thrombolytic therapy for acute ischemic stroke: summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology . 1996;  47 835-839
    PubMedGoogle Scholar
  • 48 Albers G W, Amarenco P, Easton J D, Sacco R L, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke.  Chest . 2001;  119 300S-320S
    CrossrefPubMedGoogle Scholar
  • 49 Anonymous. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke, Bethesda, MD, 1997.  National Institute of Neurological Disorders and Stroke.
    PubMedGoogle Scholar
  • 50 Furlan A, Higashida R, Wechsler L. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial.  Prolyse in Acute Cerebral Thromboembolism [see comment]. JAMA . 1999;  282 2003-2011
    CrossrefPubMedGoogle Scholar
  • 51 Ferbert A, Bruckmann H, Drummen R. Clinical features of proven basilar artery occlusion.  Stroke . 1990;  21 1135-1142
    PubMedGoogle Scholar
  • 52 Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo J G. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease.  Stroke . 1988;  19 1216-1222
    CrossrefPubMedGoogle Scholar
  • 53 Zeumer H, Freitag H J, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).  Neuroradiology . 1993;  35 159-162
    CrossrefPubMedGoogle Scholar
  • 54 Gonner F, Remonda L, Mattle H. Local intra-arterial thrombolysis in acute ischemic stroke.  Stroke . 1998;  29 1894-1900
    PubMedGoogle Scholar
  • 55 Becker K J, Monsein L H, Ulatowski J, Mirski M, Williams M, Hanley D F. Intraarterial thrombolysis in vertebrobasilar occlusion.  Am J Neuroradiol . 1996;  17 255-262
    PubMedGoogle Scholar
  • 56 Fitt G J, Farrar J, Baird A E. Intra-arterial streptokinase in acute ischaemic stroke: a pilot study.  Med J Aust . 1993;  159 331-334
    PubMedGoogle Scholar
  • 57 Phan T G, Wijdicks E F. Intra-arterial thrombolysis for vertebrobasilar circulation ischemia.  Crit Care Clin . 1999;  15 719-742
    PubMedGoogle Scholar
  • 58 Wijdicks E F, Nichols D A, Thielen K R. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience.  Mayo Clin Proc . 1997;  72 1005-1013
    PubMedGoogle Scholar
  • 59 Zeumer H. Fibrinolysis in cerebrovascular diseases of the central nervous system. In: Vinuela F, ed. Interventional Neuroradiology: Endovascular Therapy of the Central Nervous System New York: Rave Press 1992: 141-151
    Google Scholar
  • 60 Cross III T D, Moran C J, Akins P T, Angtuaco E E, Derdeyn C P, Diringer M N. Collateral circulation and outcome after basilar artery thrombolysis.  Am J Neuroradiol . 1998;  19 1557-1563
    PubMedGoogle Scholar
  • 61 Lewandowski C A, Frankel M, Tomsick T A. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.  Stroke . 1999;  30 2598-2605
    CrossrefPubMedGoogle Scholar
  • 62 Ernst R, Pancioli A, Tomsick T. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke.  Stroke . 2000;  31 2552-2557
    CrossrefPubMedGoogle Scholar
  • 63 Anonymous. Cardioembolic stroke, early anticoagulation, and brain hemorrhage. Cerebral Embolism Study Group.  Arch Intern Med . 1987;  147 636-640
    CrossrefPubMedGoogle Scholar
  • 64 Babikian V L, Kase C S, Pessin M S, Norrving B, Gorelick P B. Intracerebral hemorrhage in stroke patients anticoagulated with heparin.  Stroke . 1989;  20 1500-1503
    CrossrefPubMedGoogle Scholar
  • 65 Jaillard A, Cornu C, Durieux A. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group.  Stroke . 1999;  30 1326-1332
    PubMedGoogle Scholar
  • 66 Kay R, Wong K S, Yu Y L. Low-molecular-weight heparin for the treatment of acute ischemic stroke.  N Engl J Med . 1995;  333 1588-1593
    CrossrefPubMedGoogle Scholar
  • 67 Anonymous. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.  JAMA . 1998;  279 1265-1272
    CrossrefPubMedGoogle Scholar
  • 68 Berge E, Abdelnoor M, Nakstad P H, Sandset P M. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.  Lancet . 2000;  355 1205-1210
    CrossrefPubMedGoogle Scholar
  • 69 Diener H C, Ringelstein E B, von Kummer R. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators.  Stroke . 2001;  32 22-29
    CrossrefPubMedGoogle Scholar
  • 70 Hommel M. Fraxipaine in Ischaemic Stroke Study (FISS bis) [abstract].  Cerebrovasc Dis (suppl 4) . 1998;  8
    PubMedGoogle Scholar
  • 71 Anonymous. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.  Lancet . 1997;  349 1569-1581
    CrossrefPubMedGoogle Scholar
  • 72 Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews. Issue 4, 2001
    Google Scholar
  • 73 Bath P M, Iddenden R, Bath F J. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials.  Stroke . 2000;  31 1770-1778
    CrossrefPubMedGoogle Scholar
  • 74 Sandercock P. Intravenous unfractionated heparin in patients with acute ischemic stroke: a treatment to be used in the context of randomized trials only.  Stroke . 2001;  32 579
    PubMedGoogle Scholar
  • 75 Albers G W, Easton J D, Sacco R L, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke.  Chest . 1998;  114 683S-698S
    PubMedGoogle Scholar
  • 76 Meschia J F. Anticoagulant and defibrinogenating agents in acute ischemic stroke and cerebral venous thrombosis.  Semin Neurol . 1998;  18 461-470
    PubMedGoogle Scholar
  • 77 Sherman D G, Atkinson R P, Chippendale T. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial.  Stroke Treatment with Ancrod Trial. JAMA . 2000;  283 2395-2403
    CrossrefPubMedGoogle Scholar
  • 78 Mayberg M R, Furlan A. Ancrod: is snake venom an antidote for stroke?[letter; comment].  JAMA . 2000;  283 2440-2442
    CrossrefPubMedGoogle Scholar
  • 79 Patrono C. Aspirin as an antiplatelet drug.  N Engl J Med . 1994;  330 1287-1294
    CrossrefPubMedGoogle Scholar
  • 80 Anonymous. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.  Lancet . 1997;  349 1641-1649
    CrossrefPubMedGoogle Scholar
  • 81 Pathansali R, Bath P M. IST and CAST: some answers but more questions.  J Hum Hypertens . 1998;  12 73-74
    CrossrefPubMedGoogle Scholar
  • 82 Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci . 1996;  143 1-13
    CrossrefPubMedGoogle Scholar
  • 83 Maloney B. An analysis of the side-effects of ticlopidine. In: Hass WK, ed. Ticlopidine, Platelets and Vascular Disease New York: Springer-Verlag 1993: 117-139
    Google Scholar
  • 84 Anonymous. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.  Lancet . 1996;  348 1329-1339
    CrossrefPubMedGoogle Scholar
  • 85 Gorelick P B, Hanley Jr F D. Clopidogrel and its use in stroke patients.  Stroke . 1998;  29 1737
    PubMedGoogle Scholar
  • 86 Johnston K C, Li J Y, Lyden P D. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators.  Stroke . 1998;  29 447-453
    CrossrefPubMedGoogle Scholar
  • 87 Crockard H A, Coppel D L, Morrow W F. Evaluation of hyperventilation in treatment of head injuries.  BMJ . 1973;  4 634-640
    PubMedGoogle Scholar
  • 88 Krieger D, Adams H P, Rieke K, Hacke W. Monitoring therapeutic efficacy of decompressive craniotomy in space occupying cerebellar infarcts using brain-stem auditory evoked potentials.  Electroencephalogr Clin Neurophysiol . 1993;  88 261-270
    PubMedGoogle Scholar
  • 89 Adams H P. Guidelines for the management of patients with acute ischemic stroke: a synopsis. A Special Writing Group of the Stroke Council, American Heart Association.  Heart Disease & Stroke . 1994;  3 407-411
    PubMedGoogle Scholar
  • 90 Broderick J, Brott T, Barsan W. Blood pressure during the first minutes of focal cerebral ischemia.  Ann Emerg Med . 1993;  22 1438-1443
    PubMedGoogle Scholar
  • 91 Castillo J, Davalos A, Marrugat J, Noya M. Timing for fever-related brain damage in acute ischemic stroke.  Stroke . 1998;  29 2455-2460
    PubMedGoogle Scholar
  • 92 Ameriso S F, Wong V L, Quismorio Jr P F, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction.  Stroke . 1991;  22 1004-1009
    PubMedGoogle Scholar
  • 93 Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction.  Stroke . 1998;  29 2461-2466
    CrossrefPubMedGoogle Scholar
  • 94 Grotta J C, Pettigrew L C, Allen S. Baseline hemodynamic state and response to hemodilution in patients with acute cerebral ischemia.  Stroke . 1985;  16 790-795
    PubMedGoogle Scholar
      >